Biotechnology

Carisma Therapeutics

Carisma Therapeutics released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 45.25 M, actual EPS USD 1.0699

Carisma Therapeutics released FY2025 9 Months earnings on November 12 (EST), actual revenue USD 48.98 M, actual EPS USD 0.6104

Carisma Therapeutics released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 3.75 M), actual EPS USD -0.2338 (forecast USD -0.09)

Carisma Therapeutics released FY2025 Semi-Annual earnings on August 7 (EST), actual revenue USD 3.729 M, actual EPS USD -0.4557

Carisma Therapeutics Inc and Orthocellix Reach Merger Agreement

Carisma Therapeutics Receives NASDAQ Listing Extension

Carisma Therapeutics Inc Reports Narrowed Quarterly Loss Per Share

Carisma Therapeutics released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 3.729 M (forecast USD 1.875 M), actual EPS USD -0.2218 (forecast USD -0.12)

Carisma Therapeutics Inc expects to lose 10 cents per share in the next quarter

Carisma Therapeutics released FY2024 annual earnings on March 31 (EST), actual revenue USD 19.63 M (forecast USD 21.41 M), actual EPS USD -1.4588 (forecast USD -1.2)

Carisma Therapeutics released FY2024 Q4 earnings on March 31 (EST), actual revenue USD 3.653 M (forecast USD 5.421 M), actual EPS USD -0.4223 (forecast USD -0.1625)

Carisma Therapeutics Inc Reports Quarterly Financial Results, Loss Exceeds Expectations

Carisma Therapeutics Inc. Plans to Explore Strategic Options to Advance Liver Fibrosis and Oncology Assets

HC Wainwright & Co. Downgrades CARISMA Therapeutics Rating to Neutral

Evercore ISI Group Downgrades CARISMA Therapeutics Rating to Market Perform, Target Price Reduced to $0.70

BTIG Downgrades CARISMA Therapeutics Rating to Neutral

Carisma Therapeutics Announces Strategic Restructuring, 34% Workforce Reduction

Carisma Therapeutics released FY2024 Q3 earnings on November 7, 2024 (EST), actual revenue $3.385M (forecast $5.049M), actual EPS -0.3054 (forecast -0.2725)

Carisma Therapeutics released FY2024 9 Months Earnings on November 7, 2024 (EST), with actual revenue of 15,979,000 USD and EPS of -1.0376

Carisma Therapeutics announces changes to its board of directors

Sobr Safe

Omeros

Northann

AMC Robotics

Euda Health

Multi Ways

Dynavax Tech

Indaptus Therapeutics

Sidus Space

Kandal M Venture

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap